文献速递哮喘

全球重度哮喘特征:国际重度哮喘登记研究数据

Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry.
PubMed 文献 · Chest · 2019-11-27

国际重度哮喘登记研究纳入美国、英国、韩国、意大利及严重哮喘网络数据库(含澳大利亚、新加坡、新西兰)的4990例重度哮喘患者,描述其人口学与临床特征。患者平均年龄55.0岁,59.3%为女性,70.4%超重或肥胖,57.2%疾病控制不佳,51.1%规律间歇使用口服糖皮质激素,25.4%使用生物制剂。研究观察到国家间临床特征、治疗和生物标志物谱存在差异。

要点

  • 重度哮喘患者中女性、白种人、从未吸烟者及超重或肥胖者占多数。
  • 约半数患者规律间歇使用口服糖皮质激素,仅四分之一使用生物制剂。
  • 各国在临床特征、治疗和生物标志物谱上存在差异,需进一步研究原因。

核心结论

  • 使用统一数据集和定义描述多国重度哮喘登记中大量患者的特征,并发现国家间差异。

研究设计与样本

  • 纳入年龄≥18岁、接受GINA第5级治疗或GINA第4级仍控制不佳的重度哮喘患者,共4990例。

主要发现

  • 患者平均(SD)年龄55.0(15.9)岁,平均(SD)哮喘发病年龄30.7(17.7)岁。
  • 女性占59.3%,白种人占72.6%,从未吸烟者占60.5%,超重或肥胖者占70.4%。
  • 34.9%处于GINA第5级,57.2%疾病控制不佳。
  • 51.1%规律间歇使用口服糖皮质激素,25.4%使用生物制剂(GINA第5级患者中为72.6%)。
  • 平均(SD)年急性发作率为1.7(2.7)次。

临床怎么用

  • 临床应关注重度哮喘患者的高口服糖皮质激素使用率和低生物制剂使用率,并注意国家间差异。

局限性

  • 国家间差异是否与流行病学、环境、表型、管理体系、治疗可及性和文化因素相关尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical characteristics of the international population with severe asthma are unknown. Intercountry comparisons are hindered by variable data collection within regional and national severe asthma registries. We aimed to describe demographic and clinical characteristics of patients treated in severe asthma services in the United States, Europe, and the Asia-Pacific region. METHODS: The International Severe Asthma Registry retrospectively and prospectively collected data in patients with severe asthma (≥ 18 years old), receiving Global Initiative for Asthma (GINA) Step 5 treatment or with severe asthma remaining uncontrolled at GINA Step 4. Baseline demographic and clinical data were collected from the United States, United Kingdom, South Korea, Italy, and the Severe Asthma Web-based Database registry (including Australia, Singapore, and New Zealand) from December 2014 to December 2017. RESULTS: We included 4,990 patients. Mean (SD) age was 55.0 (15.9) years, and mean (SD) age at asthma onset was 30.7 (17.7) years. Patients were predominantly female (59.3%) and white (72.6%), had never smoked (60.5%), and were overweight or obese (70.4%); 34.9% were at GINA Step 5; and 57.2% had poorly controlled disease. A total of 51.1% of patients were receiving regular intermittent oral corticosteroids, and 25.4% were receiving biologics (72.6% for those at GINA Step 5). Mean (SD) exacerbation rate was 1.7 (2.7) per year. Intercountry variation was observed in clinical characteristics, prescribed treatments, and biomarker profiles. CONCLUSIONS: Using a common data set and definitions, this study describes severe asthma characteristics of a large patient cohort included in multiple severe asthma registries and identifies country differences. Whether these are related to underlying epidemiological factors, environmental factors, phenotypes, asthma management systems, treatment access, and/or cultural factors requires further study.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Wang E, Wechsler ME, Tran TN, et al. Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry. Chest. 2019. PMID: 31785254. doi:10.1016/j.chest.2019.10.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。